Condition (MeSH)
Adamantinoma
ClinicalTrials.gov lists 1 trial for Adamantinoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
3 sections measured, none recorded · 1 not measured yet · 1 not computed
1 of the 1 trial is tagged with Adamantinoma itself; the rest are tagged with a narrower condition beneath it.
When did Adamantinoma trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2017 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Adamantinoma trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
How many Adamantinoma trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Adamantinoma? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Does osteofibrous dysplasia progress to adamantinoma and how should they be treated? | The bone & joint journal | 2017 | Yes |
| Osteofibrous dysplasia and adamantinoma in children and adolescents: a clinicopathologic reappraisal. | The American journal of surgical pathology | 2008 | Yes |
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Adamantinoma | Lifetime prevalence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
| Adamantinoma | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Adamantinoma | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Adamantinoma | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Adamantinoma | Lifetime prevalence | 1-9 / 1 000 000 | Worldwide | Not stated | Unspecified |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Adamantinoma | 55881 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Adamantinoma | 55881 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.